AUPH - Aurinia Pharma GAAP EPS of -$0.25 misses by $0.03 revenue of $28.2M beats by $1.16M
- Aurinia Pharma press release ( NASDAQ: AUPH ): Q2 GAAP EPS of -$0.25 misses by $0.03 .
- Revenue of $28.2M (+326.0% Y/Y) beats by $1.16M .
- Maintains net revenue guidance range of $115-$135 million from sales of LUPKYNIS (voclosporin) for 2022
For further details see:
Aurinia Pharma GAAP EPS of -$0.25 misses by $0.03, revenue of $28.2M beats by $1.16M